Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1CNS 1

Conditions

Melanoma 114Carcinoma, Non-Small-Cell Lung 34Neoplasms 26Neoplasm Metastasis 19Prostatic Neoplasms 18Uveal Melanoma 16Carcinoma, Renal Cell 16Lung Neoplasms 14Pancreatic Neoplasms 13Diabetes Mellitus, Insulin-Dependent, 12 12Small Cell Lung Carcinoma 11Colorectal Neoplasms 10Carcinoma, Hepatocellular 9Uterine Cervical Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Breast Neoplasms 8Sarcoma 7Carcinoma, Transitional Cell 7Brain Neoplasms 7Stomach Neoplasms 6Mesothelioma 6Kidney Neoplasms 6Head and Neck Neoplasms 6Advanced Cancer 6Urinary Bladder Neoplasms 5Recurrence 5Ovarian Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma 5Leukemia, Myeloid, Acute 5

Interventions

Filgrastim 18Cyclophosphamide 13Etoposide 12Peripheral Blood Stem Cell Transplantation 11Ifosfamide 11Vincristine 9Carboplatin 9Radiotherapy 8Doxorubicin 8Melphalan 7Topotecan 6Temozolomide 5Granulocyte Colony-Stimulating Factor 5Busulfan 5Thiotepa 4Irinotecan 4Docetaxel 4trioctyl phosphine oxide 3cixutumumab 3Imatinib Mesylate 3Amifostine 3tanespimycin 2pegfilgrastim 2ixabepilone 2etoposide phosphate 2Oxaliplatin 2Neoadjuvant Therapy 2Microarray Analysis 2Mesna 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neuroectodermal Tumors, Primitive, Peripheral × Ipilimumab × Clear all
NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

National Cancer Institute (NCI)

Phase 1/2 Completed
140 enrolled 23 charts
CNSDermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡